Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists (GIP/GLP-1 RAs) are emerging as effective treatments for obesity and cardiometabolic disease. This study evaluated physician perceptions of the safety and efficacy of semagl...

Full description

Saved in:
Bibliographic Details
Main Authors: Srikanth Krishnan, Pratyaksh K. Srivastava, Jayram Attaluri, Rebecca Nayeri, Dhananjay Chatterjee, Jay Patel, Ali Nsair, Matthew Budoff, Arash Nayeri
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Journal of Cardiovascular Development and Disease
Subjects:
GIP GLP-1 receptor agonist
metabolic syndrome
obesity
weight loss
semaglutide
tirzepatide
Online Access:https://www.mdpi.com/2308-3425/12/1/19
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items